SITEMAP

ä¯ÀÀÁ¿

¸´Òé¾ö¶¨±»³·Ïú(Éæ¿óÅоöÈ«ÎÄ)·¨¿ÍµÛ¹ú£¬»ãͨ²Æ¾­ÊÖ»ú°æÏÂÔØ

×÷Õߣºadmin ·¢²¼Ê±¼ä£º2024-05-17

¡¡¡¡¸´Òé¾ö¶¨±»³·Ïú(Éæ¿óÅоöÈ«ÎÄ)·¨¿ÍµÛ¹ú£¬»ãͨ²Æ¾­ÊÖ»ú°æÏÂÔØ±¾×÷Æ·ËùÏÔʾµÄͼƬ¡¢»­Ïñ¡¢×ÖÌå¡¢ÒôÀֵİæÈ¨Äܹ»Ðè°æÈ¨·½·ÖÍâÊÚȨ£¬ÇëÂ¡ÖØÀûÓá£

¡¡¡¡ÍøÕ¾¹©Ó¦µÄµ³ÕþÖØÐĸÉϵʵÖÊ(°îÆì¡¢°î»Õ¡¢µ³»Õ..)Ö÷ÒâÕýÔÚÓÚÅäºÏ°î¶È²ßÂÔÐû³Æ£¬½öÏÞ¸ö±ð½øÐÞ·ÖÏíÀûÓ㬽ûÖ¹ÓÃÓÚÈÎºÎ¹ã¸æºÍÉÌÓÃÖ÷Òâ¡£

¡¡¡¡Å©²úÎï»ðËÙ¼ì²â±¾ÊÂW1101-2Ëٲ⿨·¨¼ì²âÅ©²ÐµÄµÀÀí¼°Ëٲ⿨ÀûÓÃ-΢¿Î¼þ

¡¡¡¡Å©²úÎï»ðËÙ¼ì²â±¾ÊÂW1101-2Ëٲ⿨·¨¼ì²âÅ©²ÐµÄµÀÀí¼°Ëٲ⿨ÀûÓÃ-΢¿Î¼þ

¡¡¡¡Chapter 16 – In Vivo Evaluation of Oral Dosage Form Performance

¡¡¡¡°ÔÆø!×î¸ß·¨¸±Ôº³¤Ç×ÅкÓɽ²¿°ÜËßÒò˵Àí²»³äÓ¯Ö¤¾Ý¿÷¿Õ,¸´Ò鶨¶á±»È¡Ïû(Éæ¿óÅжÏÈ«ÎÄ)·¨¿ÍµÛ°î

¡¡¡¡°ÔÆø!×î¸ß·¨¸±Ôº³¤Ç×ÅкÓɽ²¿°ÜËßÒò˵Àí²»³äÓ¯Ö¤¾Ý¿÷¿Õ,¸´Ò鶨¶á±»È¡Ïû(Éæ¿óÅжÏÈ«ÎÄ)·¨¿ÍµÛ°î

¡¡¡¡MenuItem 10 {Chapter 10} Medium-to-longer-term debt£º{ 10 }²Ëµ¥10ÕÂÖкã¾ÃÕ®Îñ

ÍøÓÑͲÛ

ÍÆ¼öÔĶÁ

´´Òµ¹ÊÊÂ

ÓÑÇéÁ´½Ó

FXCGÍâ»ã Íâ»ãƽ̨ Íâ»ã½»Ò× MT4Íâ»ãÆ Íâ»ã½»Ò×